and so in that light, peter huber, another one of our senior fellows and paul howard, director of the center for medical progress, have put out a new paper which you have in your folders. which argues that the fda is a little behind the curve in addressing how these new developments, new scientific developments, can help accelerate the discovery and development, approval and marketing of new treatments for disease. so we are going to hear from both peter and paul today and we brought two additional panels with a soy think can't eliminate a lot of this discussion. we are going to also from the ceo of emerging biotech company called alter genex which specializes in biotech companies, specialist in the development of treatments for ultra rare diseases. before he was at alter genex was with another company that specialized in this area called one of the largest and most successful biotech companies. alter genex has had some success. it went public just the last genuine out as a mark of capital of 2.3 windows which 10 years ago was unheard of but has become more common as companies have go

so peter huber and paul howard the center for medical progress put out a new paper it is a little behindhe curve with these new developments of scientific developments can help accelerate the discovery and development of approval and marketing for their treatment of disease. the ceo of an emerging biotech company that specializes in the development of treatments of ultra rare diseases before that was with another company with a largest most successful biotech energies in this area they have had success with a market cap of 2.3 million dollars which 10 years ago was unheard of but that is more common as companies have gotten more sophisticated we're also going to hear from the vice president of scientific and medical affairs at the pancreatic action network to tell us that the patient's level the challenges to work with companies to take advantage of personalize precision madison -- medicines might think we will start to get the ball rolling. i just want to have each of you tell us you have had experience in pancreatic cancer world so what are the challenges? how does that very between pa